axt107 peptide targets VEGF and three other pathways that promote blood vessel growth - Elamipretidepeptide is designed to both block pro-angiogenic (VEGF) signals and promote vascular stabilization AXT107 Peptide: A Promising Advancement in Treating Retinal Diseases

PEDFpeptide The landscape of treating vision-threatening retinal diseases is continually evolving, with researchers actively seeking innovative therapeutic solutions. Among these, the AXT107 peptide, also known as gersizangitide, has emerged as a significant area of investigation.2025年7月16日—The lead clinical candidate,integrin regulating peptide AXT107(gersizangitide), has a novel mechanism of action that inhibits ... This collagen IV-derived peptide demonstrates a novel dual mechanism of action, targeting key pathways involved in the progression of conditions like diabetic macular edema and wet age-related macular degeneration. Its development represents a potential breakthrough, offering hope for improved outcomes in patients suffering from these debilitating diseases.

The efficacy of AXT107 lies in its ability to simultaneously address two critical aspects of neovascularization in the eye. Firstly, it targets VEGF and other pathways that promote abnormal blood vessel growth.New Peptide Could Improve Treatment for Vision- ... Specifically, AXT107 inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2), a crucial component in the signaling cascade that leads to the formation of leaky and fragile new blood vesselsSynthetic peptide outlasts macular degeneration med .... By blocking these signals, AXT107 aims to prevent the further development of these problematic vessels.AXT107 (Gersizangitide) is a mimetic peptidederived from collagen IV, binds integrins αvβ3 and α5β1 (Kd=1.29 and 2.21 nM), disrupts VEGFR2-β3 complex ...

Secondly, and distinctively, AXT107 is designed to both block pro-angiogenic (VEGF) signals and promote vascular stabilization.作者：RL e Silva·2023·被引用次数：11—AXT107, a collagen-derived peptidethat binds integrins α v β 3 and α 5 β 1 with high affinity, suppresses vascular endothelial growth factor (VEGF) signaling. This is achieved through its interaction with the Tie2 signaling pathway. Research indicates that AXT107 treatment dissociates α5 and β1 integrins, which in turn leads to the translocation and activation of Tie2 at endothelial cell-cell junctions. This activation of Tie2 signaling is crucial for promoting vascular stability and integrity, counteracting the damaging effects of abnormal vessel growth. Furthermore, AXT107 resolves TNFα-induced vascular inflammation in endothelial cells by converting the endogenously released Ang2 into an agonist of Tie2 signaling. This dual action of inhibiting pathological angiogenesis while simultaneously promoting vascular health makes AXT107 a compelling therapeutic candidate.

The scientific community has shown considerable interest in AXT107 peptide. Numerous studies have explored its mechanism of action and potential clinical applications. For instance, research published in IOVS and other journals highlights that AXT107, a collagen IV-derived peptide, which blocks signaling through VEGF receptors and activates Tie2, suppresses vascular leakage in ischemic retinopathy.New peptide could improve treatment for vision-threatening ... This ability to stop abnormal blood vessels in the eye from leaking vision-blocking fluids is a critical factor in preserving vision.2021年1月5日—The first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity ofAXT107in patients with Diabetic Macular ...

Pre-clinical studies have demonstrated the peptide's effectiveness. In one study, AXT107 suppressed abnormal vascular leakage for two months while aflibercept suppressed leakage for one month, suggesting a potentially longer duration of action.In sum, AXT107is designed to both block pro-angiogenic (VEGF) signals and promote vascular stabilization(via Tie2 activation), making it a promising ... Another study indicated that a combination of AXT107 and Eylea suppressed subretinal blood vessel growth better than either treatment alone.The collagen IV-derived peptide AXT107 suppresses ... These findings underscore the potential of AXT107 as a standalone therapy or in combination with existing treatments.

The development of AXT107 is being spearheaded by AsclepiX TherapeuticsThe Tie2 signaling pathway in retinal vascular diseases. The company has advanced the integrin regulating peptide AXT107 through clinical trials, aiming to establish its safety and efficacy in humans. The AXT107 peptide is a mimetic peptide derived from collagen IV, and its developers have highlighted its novel mechanism of action. Clinical trials have investigated the safety and bioactivity of AXT107 in patients with diabetic macular edema. The first patient was dosed in a Phase 1/2a clinical trial in January 2021, with subsequent enrollment completions in trials for DME in 2024. These trials are crucial for gathering data on AXT107's performance in a clinical setting.

A significant aspect of AXT107's development is its administration.Experimental Drug Delivers One-Two Punch to Vision Loss Studies suggest that AXT107 is safe for intravitreal injection, a common method for delivering medications to the back of the eye. Researchers have further indicated that yearly dosing of AXT107 may have promise for retinal diseases, supporting potentially once-a-year dosing in the clinic. This infrequent dosing schedule could significantly improve patient compliance and convenience compared to more frequent treatment regimensGersizangitide (AXT107) | VEGFR2-β3 inhibitor. The peptide's ability to form a gel within the eye, as noted in some research, may contribute to its sustained release and prolonged therapeutic effect, allowing it to inhibit disease for longer periods of time.

The AXT107 peptide is chemically described as AXT107, a collagen-derived peptide that binds integrins αvβ3 and α5β1 with high affinity, and it binds integrins αvβ3 and α5β1 (Kd=1.29 and 22024年5月6日—AsclepiX's lead clinical candidate,integrin regulating peptide AXT107, has a novel mechanism of action that inhibits neovascularization ....21 nM), disrupts VEGFR2-β3 complex.AsclepiX Therapeutics Completes Enrollment in ... This specific binding profile is central to its therapeutic action. The peptide of SEQ ID NO:3 is also referred to as AXT107 or as SP2043.

The potential impact of AXT107 extends to various retinal conditions. It shows promise for improving treatment for degenerative retinal diseases by offering a more robust suppression of abnormal blood vessel growth.作者：RL e Silva·2023·被引用次数：11—AXT107, a collagen-derived peptidethat binds integrins αvβ3 and α5β1 with high affinity, suppresses vascular endothelial growth factor ... While not directly mentioned in the primary search results, related search terms like "peptides for vision loss" and "best peptides for vision" indicate a broader interest in peptide-based therapies for ocular health, further contextualizing the significance of AXT107's development2017年1月26日—The researchers found that theAXT107 peptideand aflibercept significantly suppressed new vessel growth, and the combination of AXT107 and ....

In summary, the AXT107 peptide represents a significant advancement in the field of ophthalmology. Its unique dual mechanism of action, targeting both the inhibition of pathological angiogenesis and the promotion of vascular stabilization, coupled with its potential for infrequent intravitreal administration, positions it as a highly promising therapeutic for a range of retinal diseasesAvastin treatment for eye disease – MaculaCenter.com. Ongoing clinical trials will be pivotal in confirming its efficacy and safety, paving the way for a new era of treatment for patients facing vision loss.